These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32527703)

  • 1. Implementation of hepatitis C screening within a pharmacist-managed medication-assisted therapy opioid use disorder protocol program.
    Llayton CK; Harlow CP; Burris JN; Rhodes J
    J Am Pharm Assoc (2003); 2020; 60(6):e307-e311. PubMed ID: 32527703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center.
    Isho NY; Kachlic MD; Marcelo JC; Martin MT
    J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
    Palmer E; Hart S; Freeman PR
    J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
    Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
    J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovating the Model for Student Pharmacists to Increase Access to Hepatitis C Testing (Project IMPACT).
    Januszka J; Notarianni V; Devenny E; Harris E
    J Am Pharm Assoc (2003); 2023; 63(4):1217-1221. PubMed ID: 37037394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the proportion of patients with hepatitis C treated before and after initiation of an ambulatory pharmacist-led hepatitis C program: A retrospective analysis.
    Ortiz J; Rasch M
    J Am Pharm Assoc (2003); 2023; 63(1):440-446. PubMed ID: 36272941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
    Dong BJ; Lopez M; Cocohoba J
    J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment.
    Brown JL; Gause NK; Lewis D; Winhusen T
    J Subst Abuse Treat; 2017 May; 76():77-80. PubMed ID: 28162850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indiana community pharmacist preceptors' knowledge and perceptions of medication-assisted treatment.
    Davenport ES; Arnett SJ; Nichols MA; Miller ML
    J Am Pharm Assoc (2003); 2020; 60(3S):S20-S28.e4. PubMed ID: 32094038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of a postgraduate year 2 ambulatory care pharmacy residency program utilizing Medicare annual wellness visits within primary care.
    Pierce KN; Woodhouse A; Simpson G
    J Am Pharm Assoc (2003); 2022; 62(1):260-263. PubMed ID: 34465525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans.
    Kirby T; Connell R; Linneman T
    Am J Health Syst Pharm; 2021 Feb; 78(4):301-309. PubMed ID: 33289022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist-driven multidisciplinary pretreatment workup process for hepatitis C care: A novel model for same-day pretreatment workup.
    Houck KK; Ifeachor AP; Fleming BS; Andres AM; O'Donovan KN; Johnson AJ; Liangpunsakul S
    J Am Pharm Assoc (2003); 2019; 59(5):710-716. PubMed ID: 31227418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacy programmatic perspectives on use of direct-acting antivirals for acquired hepatitis C infection in solid organ transplant recipients.
    Crona L; Berry H; Byrns J; Campbell U
    Am J Health Syst Pharm; 2020 Jul; 77(14):1149-1152. PubMed ID: 32537658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of a vaccine screening program at an independent community pharmacy.
    Rhodes LA; Branham AR; Dalton EE; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2017; 57(2):222-228. PubMed ID: 27964886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency medicine pharmacist market perceptions: Emergency medicine residency program directors and directors of pharmacy.
    Hu D; Myres J
    J Am Pharm Assoc (2003); 2020; 60(4):541-547.e2. PubMed ID: 32115391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.